CrystalGenomics is a commercial stage biopharmaceutical company that is dedicated to the discovery and development of novel pharmaceuticals with innovative platform technologies to address significant unmet medical needs in the areas of infectious disease, oncology, and inflammatory diseases. The Company is headquartered in Korea and has a US presence for global development in California, and it is publicly traded on the KOSDAQ exchange (083790). CrystalGenomics has a product on the market and is developing several novel drug candidates in different therapeutic areas. The marketed product is Acelex® (polmacoxib), a next generation NSAID for the treatment of signs and symptoms of osteoarthritis. The first clinical stage program is CG-745, an epigenetic agent applicable to various types of solid and liquid tumors and currently, phase 2 clinical trials are ongoing for pancreatic cancer and MDS. The second clinical stage program is CG-549, a novel class antibiotic for MRSA where its phase 2a skin infection study in the US had been completed with a positive outcome of 100% clinical cure rate. The Company's therapeutic candidates are discovered and developed through its proprietary discovery platform technology which utilizes the integrated technologies of the SPS™ (technology for structure determination), the SCP™ (technology for the generation of lead compounds) and the SDF™(technology used for lead optimization) technologies. By leveraging its capabilities and the know-how in novel drug discovery and development, CrystalGenomics will continue to strive in making significant contributions for improving human health. For more information, please visit: www.cgxinc.com or www.crystalgenomics.com.
View Top Employees from CrystalGenomics, Inc.Website | http://www.crystalgenomics.com/en/index.php |
Revenue | $12 million |
Employees | 23 (10 on RocketReach) |
Founded | 2000 |
Address | 5f Tower a Korea Bio Park 700 Daewangpangyo-ro, Seongnam, Gyeonggi-do 463-400, KR |
Phone | +82 31-628-2700 |
Fax | +82 31-628-2701 |
Technologies |
JavaScript,
HTML,
Google Analytics
+6 more
(view full list)
|
Industry | Biotechnology Research, Drug Stores & Pharmacies, Drug Discovery, Retail, Pharmaceuticals |
Web Rank | 18 Million |
Keywords | Hdac |
Competitors | Astex Pharmaceuticals, Inc. (US), Intra-Cellular Therapies, Milestone Pharmaceuticals, Inc., Trevena Inc, Vidac Pharma |
SIC | SIC Code 283 Companies, SIC Code 28 Companies |
NAICS | NAICS Code 32 Companies, NAICS Code 32541 Companies, NAICS Code 325 Companies, NAICS Code 3254 Companies |
Looking for a particular CrystalGenomics, Inc. employee's phone or email?
The CrystalGenomics, Inc. annual revenue was $12 million in 2024.
Pilgoo Lee is the Director of CrystalGenomics, Inc..
10 people are employed at CrystalGenomics, Inc..
CrystalGenomics, Inc. is based in Seongnam, Gyeonggi-do.
The NAICS codes for CrystalGenomics, Inc. are [32, 32541, 325, 3254].
The SIC codes for CrystalGenomics, Inc. are [283, 28].